Bruker at Virtual US HUPO 2021

Bruker at Virtual US HUPO

Watch the presentations from Bruker’s Virtual US HUPO Seminar

Didn’t have a chance to attend US HUPO?  Be sure to playback our presentations from March 9th or download our posters and literature. Be sure to also visit our Partners info.

Access the presentation from March 9th

Talk title: Real-time search using PaSER and the extended capabilities of the timsTOF Pro

Computationally, real-time database search in proteomics has been difficult because the time to search and assign a fragment ion spectrum to a peptide sequence can take longer than the rate of acquisition. This is particularly true when the search space is large including PTMs or semi-specific search parameters. Here, using massively parallelized search capabilities on a GPU called PaSER we can effectively perform the database search at the same rate as data acquisition, even under difficult search parameters including PTMs and enyme specificity. Additionally, in this talk we will describe the extended capabilities of the timsTOF Pro in prm-PASEF and dia-PASEF modes.  


Chris Adams, PhD
Business Development Bioinformatics,
Bruker Daltonics

Chris Adams is the Business Development Director Bioinformatics for Bruker Daltonics, where he has been since Feb. 2018. Prior to his time at Bruker Daltonics he was the Director of proteomics at the Stanford University Mass Spectrometry (SUMS) Laboratory where he had held increasing roles over 10 years. Chris received his PhD from Uppsala University, Sweden within the department of biological and medical mass spectrometry under the guidance of Professor Roman Zubarev. Prior to graduate school Chris worked at various research positions with Amgen and Baxter Biosciences. He is a Southern California native and in his free time enjoys outdoor activities with his wife, two daughters and dog that include boating and snow skiing.

Talk title: Enabling Deep and Rapid plasma proteomes at scale with Proteograph™ and timsTOF Pro

Productive biomarker discovery studies are resource-limited requiring complex workflows that operate with trade-offs in throughput, scalability, coverage, and precision. Thus, there is a need for new technological solutions for large-scale proteomic studies. Herein, we describe Proteograph™, a novel platform leveraging the nano-bio interactions of nanoparticles and their distinct biophysicochemical properties in forming protein coronas for deep and unbiased proteomic sampling.


Shadi Ferdosi, PhD
Scientist at Seer

Dr. Shadi Ferdosi is an experienced Scientist at Seer, working cross functionally between assay development, mass spectrometry, and proteomics data analysis. Dr. Ferdosi joined Seer very early on after finishing her PhD at Arizona State University, exploring the diagnostic and prognostic capacity of blood plasma and serum glycans in different types of cancer.

Talk title: Plasma proteomics during a pandemic with a focus on COVID-19 and trauma patients

Over 100 million people around the world have tested positive for the beta coronavirus SARS-CoV-2 from late 2019 to February 1st, 2021. COVID-19 has been characterized by elevated mortality with approximately 2.24 million deaths, primarily due to thrombo-inflammatory complications that impair lung perfusion and systemic oxygenation in the most severe cases. Over the same time period we developed a plasma proteomics pipeline using the Evosep One and timsTOF Pro system to explore systemic alterations in numerous injury and disease states. Similarities between COVID-19 and trauma, the number one cause of death for individuals under 45 with approximately 5.8 million annual deaths worldwide, lead to the exploration of a therapeutic intervention that activates the fibrinolytic system.


Kirk Hansen, PhD
Professor, University of Colorado
CU Anschutz
Biochemistry and Molecular Genetics

Dr. Kirk C. Hansen is a world-leading expert in the field of quantitative and extracellular matrix proteomics. Former UCSF and CalTech alumnus, over the past decade Dr. Hansen and his lab have invested in the development and translational application of analytical strategies for the detection and quantification of proteins in health and disease, with a particular focus on the extracellular matrix. As Director of the University of Colorado, School of Medicine, Proteomics Facility Dr. Hansen has collaborated with a wide range of scientists and clinicians on a diverse set of research and clinical projects. This effort has resulted in over one hundred publications in less than 6 years.